Insider Buying: Xencor, Inc. (XNCR) Major Shareholder Buys $524,000.00 in Stock
Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 25,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was bought at an average cost of $20.96 per share, for a total transaction of $524,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Xencor, Inc. (XNCR) opened at 19.94 on Monday. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The company’s market capitalization is $935.70 million. The company has a 50-day moving average price of $22.56 and a 200 day moving average price of $23.00.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The business had revenue of $13.34 million during the quarter, compared to the consensus estimate of $8.15 million. Equities research analysts anticipate that Xencor, Inc. will post ($1.17) earnings per share for the current year.
Several equities analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a research report on Wednesday, May 10th. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $29.33.
Several large investors have recently bought and sold shares of XNCR. Equitec Specialists LLC acquired a new position in Xencor during the second quarter worth about $116,000. SG Americas Securities LLC increased its position in Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,252 shares in the last quarter. Legal & General Group Plc increased its position in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. Airain ltd acquired a new position in Xencor during the first quarter worth about $213,000. Finally, Citadel Advisors LLC acquired a new position in Xencor during the second quarter worth about $224,000. Institutional investors and hedge funds own 73.53% of the company’s stock.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.